MedTrace Logo

Effect of Bile Acids on GLP-1 Secretion

NCT01666223 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-24

No results posted yet for this study

Summary

The purpose of this study is to describe the physiological, pathophysiological and potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1) secretion in human glucose homeostasis.

Conditions

Interventions

DRUG

Colesevelam

Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.

DRUG

Chenodeoxycholic Acid

1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.

OTHER

saline

100 ml saline

DRUG

Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg

Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Morten Hansen, MD · Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666223 on ClinicalTrials.gov